Section Arrow
Quote
ACET.NASDAQ
- Adicet Bio
(Financial Status)
Quotes are at least 15-min delayed:2025/06/26 16:12 EDT
Last
 0.6706
+0.0126 (+1.91%)
Day High 
0.68 
Prev. Close
0.658 
1-M High
0.84 
Volume 
614.65K 
Bid
0.6706
Ask
0.677
Day Low
0.64 
Open
0.6637 
1-M Low
0.625 
Market Cap 
54.42M 
Currency USD 
P/E -- 
%Yield 12.68 
10-SMA 0.7 
20-SMA 0.72 
50-SMA 0.67 
52-W High 1.7 
52-W Low 0.4471 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.29/-0.73
Enterprise Value
68.52M
Balance Sheet
Book Value Per Share
1.95
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
VORVor Biopharma0.89+0.3356+60.53%-- 
ADILAdial Pharmaceuticals0.4698+0.2238+90.98%-- 
PSTVPlus Therapeutics0.3666+0.0516+16.38%-- 
ALTAltimmune3.61-4.1-53.18%-- 
ASBPAspire Biopharma Holdings Inc.0.306+0.0664+27.71%-- 
Quotes are at least 15-min delayed：2025/06/26 16:12 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.